EARNEST Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

EARNEST Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-112	Closed	-$13K	–	1164
2023 Q3	$13K	Hold	112	–	–	﹤0.01%	574
2023 Q2	$11.5K	Hold	112	–	–	﹤0.01%	600
2023 Q1	$12.2K	Hold	112	–	–	﹤0.01%	581
2022 Q4	$12.7K	Hold	112	–	–	﹤0.01%	567
2022 Q3	$7K	Hold	112	–	–	﹤0.01%	698
2022 Q2	$9K	Hold	112	–	–	﹤0.01%	645
2022 Q1	$12K	Hold	112	–	–	﹤0.01%	613
2021 Q4	$12K	Hold	112	–	–	﹤0.01%	641
2021 Q3	$12K	Hold	112	–	–	﹤0.01%	618
2021 Q2	$10K	Hold	112	–	–	﹤0.01%	675
2021 Q1	$10K	Hold	112	–	–	﹤0.01%	650
2020 Q4	$8K	Hold	112	–	–	﹤0.01%	704
2020 Q3	$9K	Buy	+112	New	+$7.71K	﹤0.01%	611

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

EARNEST Partners's HZNP Position: Q4 2023 in Review

EARNEST Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 112 shares — an estimated $13K sold.

EARNEST Partners first reported a position in HZNP in Q3 2020 and held it in 13 quarters. The position peaked at $13K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

EARNEST Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 112 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $13K.
EARNEST Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 13 quarters.
EARNEST Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $13K in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.